Future Perspectives of Bone Tissue Engineering with Special Emphasis on Extracellular Vesicles

Peer reviewe

Treatment for Central Centrifugal Cicatricial Alopecia - Delphi Consensus Recommendations

There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely. To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA. We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed. In Round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in Round 2. After the final Round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus. This study included only English-speaking, US-based dermatologists and did not consider non-pharmacological therapies. Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA

Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients

BACKGROUND: The major concern regarding the use of low-dose oral minoxidil (LDOM) in the treatment of hair loss is the potential risk of systemic adverse effects.OBJECTIVE: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.METHODS: Retrospective multicenter study of patients treated with LDOM for at least 3 months as a treatment for any type of alopecia.RESULTS: A total of 1404 patients [943 women (67.2%) and 461 men (32.8%)] with a mean age of 43 years (range 8-86) were included. From them, the dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%) which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%) and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed.LIMITATIONS: Retrospective design, lack of a control group.CONCLUSION: LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients stopped the treatment due to adverse effects